Acute Dietary Nitrate Supplementation Improves Flow Mediated Dilatation of the Superficial Femoral Artery in Healthy Older Males by Walker, MA et al.
nutrients
Article
Acute Dietary Nitrate Supplementation Improves
Flow Mediated Dilatation of the Superficial Femoral
Artery in Healthy Older Males
Meegan A. Walker 1,* , Tom G. Bailey 1,2 , Luke McIlvenna 3, Jason D. Allen 3,4 ,
Daniel J. Green 5 and Christopher D. Askew 1,6
1 VasoActive Research Group, School of Health and Sport Sciences, University of the Sunshine Coast,
Sippy Downs, QLD 4556, Australia; tom.bailey@uq.edu.au (T.G.B.); caskew@usc.edu.au (C.D.A.)
2 School of Human Movement and Nutrition Sciences, University of Queensland, St Lucia,
QLD 4072, Australia
3 Institute for Health and Sport, College of Sport and Exercise Science, Victoria University, Melbourne,
VIC 3031, Australia; luke.mcilvenna@live.vu.edu.au (L.M.); ja6af@virginia.edu (J.D.A.)
4 Department of Kinesiology, University of Virginia, Charlottesville, VA 22903, USA
5 School of Sport Sciences, Exercise and Health, University of Western Australia, West Perth, WA 6872,
Australia; danny.green@uwa.edu.au
6 Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service, Birtinya, QLD 4575, Australia
* Correspondence: mwalker@usc.edu.au; Tel.: +61-7-5456-3751
Received: 28 March 2019; Accepted: 24 April 2019; Published: 26 April 2019


Abstract: Aging is often associated with reduced leg blood flow, increased arterial stiffness, and
endothelial dysfunction, all of which are related to declining nitric oxide (NO) bioavailability. Flow
mediated dilatation (FMD) and passive leg movement (PLM) hyperaemia are two techniques used
to measure NO-dependent vascular function. We hypothesised that acute dietary nitrate (NO3−)
supplementation would improve NO bioavailability, leg FMD, and PLM hyperaemia. Fifteen
healthy older men (69 ± 4 years) attended two experiment sessions and consumed either 140 mL of
concentrated beetroot juice (800 mg NO3−) or placebo (NO3−-depleted beetroot juice) in a randomised,
double blind, cross-over design study. Plasma nitrite (NO2−) and NO3−, blood pressure (BP),
augmentation index (AIx75), pulse wave velocity (PWV), FMD of the superficial femoral artery, and
PLM hyperaemia were measured immediately before and 2.5 h after consuming NO3− and placebo.
Placebo had no effect but NO3− led to an 8.6-fold increase in plasma NO2−, which was accompanied
by an increase in FMD (NO3−: +1.18 ± 0.94% vs. placebo: 0.23 ± 1.13%, p = 0.002), and a reduction
in AIx75 (NO3−: −8.7 ± 11.6% vs. placebo: −4.6 ± 5.5%, p = 0.027). PLM hyperaemia, BP, and
PWV were unchanged during both trials. This study showed that a dose of dietary NO3− improved
NO bioavailability and enhanced endothelial function as measured by femoral artery FMD. These
findings provide insight into the specific central and peripheral vascular responses to dietary NO3−
supplementation in older adults.
Keywords: inorganic nitrate; beetroot juice; nitric oxide; endothelial function; arterial stiffness; blood
flow; cardiovascular risk
1. Introduction
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide [1] and
there is considerable interest in strategies to promote healthy aging. Several factors contribute to
the age-related decline in cardiovascular health, and a central determinant is the bioavailability of
nitric oxide (NO). Nitric oxide is the primary regulator of vascular tone and it has an essential role
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in the prevention of platelet aggregation, inhibition of vascular smooth muscle cell proliferation,
and the prevention of atherosclerotic plaque formation [2–4]. Older adults demonstrate reduced
NO bioavailability [5], which contributes to age-related increases in blood pressure and vascular
stiffness [6] and the associated risk of cardiovascular events [3,7]. Impairments in NO bioavailability
may also lead to a reduction in limb blood flow, possibly through the role of NO in functional
sympatholysis [8] and endothelium-dependent vasodilation [9,10]. The decrease in blood flow is
particularly evident in the legs [11,12] and is associated with reduced muscle function and diminished
exercise capacity. Age-related reductions in leg blood flow are exacerbated in those with chronic
conditions such as peripheral arterial disease [13] and heart failure [14]. Strategies to improve NO
bioavailability, and thereby improve vascular function and enhance leg blood flow, may help in the
prevention and management of age-related cardiovascular impairments.
Vascular NO is produced endogenously from L-arginine via endothelial nitric oxide synthase
(eNOS), but it can also be generated from exogenous supplementation via the diet. Natural food sources
high in inorganic nitrate (NO3−), such as beetroot (Beta vulgaris), can be reduced to nitrite (NO2−) by
oral bacteria [15–17] and further reduced to NO by a wide variety of enzymatic and non-enzymatic
pathways [18–20]. Reduction of NO2− to NO is facilitated in ischemic conditions [19,21], suggesting
that this pathway of NO generation may protect the tissues from metabolic stress. Inorganic NO3−
supplements, such as concentrated beetroot juice, have been shown to acutely improve exercise tolerance
in older adults [22] and in patients with peripheral arterial disease [23,24]. Vascular mechanisms
may contribute to this enhancement in exercise tolerance [25,26], as NO3− supplements have been
shown to induce a temporary reduction in blood pressure [27] and arterial stiffness [28–30] in older
adults. Increased NO bioavailability through NO3− supplementation may promote vessel dilation [31],
increasing blood flow, which might contribute to improved exercise tolerance in older adults.
Flow mediated dilatation (FMD) is a well-established measure of endothelial function [32] where
age-related decreases are associated with increased cardiovascular risk [33,34]. There are some studies
supporting the link between NO3− supplementation and increased FMD in the brachial artery of the
arm in older adults [28–30,35]. While FMD is most commonly assessed at the arm, arm-FMD may
not provide insight into the age-specific impairments that manifest in the legs. There is evidence
that vascular impairments with ageing are limb specific [11,36] and arm-FMD is not predictive of
leg-FMD [37]. Moreover, brachial FMD does not reflect disease severity in lower-limb peripheral
arterial disease [38], although there may be a common link to elevated levels of reactive oxygen
species [39]. Identifying whether dietary NO3− has an effect on FMD in the legs will help to establish
whether dietary NO3− may improve exercise tolerance through a mechanism that involves improved
endothelial function.
Measurement of the hyperaemic response to passive leg movement provides an alternative index
of vascular function and one that is specific to the lower limbs. While FMD, described above, is a
measure of conduit artery function, the blood flow response during passive leg movement likely
reflects endothelial function at the level of the downstream arterioles. Passive leg movement delivers
mechanical stimulation without altering metabolic demand [40], initiating a hyperaemic response
that is highly dependent on NO bioavailability [41,42]. Consistent with this, passive leg movement
hyperaemia declines with age [43], is greater in those who exercise regularly compared to sedentary
individuals [44], and is diminished in cardiovascular disease [13,41]. Passive leg movement hyperaemia
provides an opportunity to test the influence of NO3− supplementation on NO-dependent leg blood
flow in older adults.
The aim of this study was to determine whether an acute dose of inorganic dietary NO3−
would improve femoral artery FMD, increase passive leg movement hyperaemia, and reduce
arterial stiffness. Improvements in these parameters would suggest enhanced vascular function
as a mechanism that contributes to improvements in exercise tolerance in older adults following dietary
NO3− supplementation.
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2. Methods
2.1. Ethical Approval
This study conformed with the latest version of the Declaration of Helsinki, it was registered
with the Australian New Zealand Clinical Trials Registry (12616001028493), and all procedures were
approved by the University of the Sunshine Coast Human Research Ethics Committee. Participants
were taken through the study design in detail and any potential risks were explained prior to obtaining
written informed consent.
2.2. Participants
Fifteen healthy males aged 60–75 years participated in the study. All participants provided
a full medical history including medication and supplement use. Ankle brachial index (ABI) was
calculated to ensure an absence of blood flow impairments (ABI >1.0). Participants were excluded
if they reported taking anti-hypertensive medication, were a current smoker, had been diagnosed
with a cardiovascular disease, exceeded current physical activity guidelines (more than 30 min·day−1,
5 days·week−1 of moderate intensity exercise), or if they had any communicable diseases. Individuals
who indicated taking fish oil supplements (n = 4) were instructed to refrain for six weeks prior to
study participation, as some fish oil supplements can have an anti-hypertensive effect [45] which might
mask any impact of NO3−. Participants taking low doses of statins (≤5 mg·day−1 Resuvastatin or
≤10 mg·day−1 Atorvastatin) were included.
2.3. Overview of Study Design
Following an initial visit for screening and test familiarisation, participants attended the laboratory
twice for a series of tests. Participants were instructed to avoid vigorous exercise, caffeine, and alcohol
for 24 h before each visit and all participants were asked to abstain from using mouthwash throughout
the study to preserve entero-salivary NO2− generation [15]. For three days prior to each experimental
visit, participants were instructed to avoid high NO3− foods and they were provided with a list of low
NO3− foods they could use as substitutes. Food substitution lists were assembled from data presented
by Santamaria et al [46] and Hord et al [20].
During each visit, participants were given either NO3−-rich beetroot juice or a placebo using a
randomised, double-blind, cross-over design. During experimental visits, blood pressure, plasma
NO3− and NO2−, augmentation index, carotid-femoral pulse wave velocity, leg FMD, and passive leg
movement hyperaemia were measured before and after NO3− and placebo.
2.4. Experimental Visits
Participants and researchers were blinded to the condition (NO3− vs. placebo) and experiment
trials were separated by 7 ± 2 (SD) days to ensure complete wash-out of NO3− supplements. On
arrival, participants rested quietly in a seated position for 15 min before brachial blood pressure was
measured three times on each arm using a Carescape V100 Vital Signs Monitor (GE Medical Systems
Information Technologies, Chicago, IL, USA) and a blood sample was drawn from an antecubital vein
for analysis of plasma NO3− and NO2−. Participants moved to a supine position on a treatment table,
and following another 15 min rest, arterial stiffness was assessed by measuring augmentation index
and pulse wave velocity. Following a further 10 min period of rest, FMD of the superficial femoral
artery was determined. Participants then moved to the leg-kick ergometer and rested in the seat
for 15 min before baseline (resting) common femoral artery diameter and blood flow velocity were
measured for the determination of leg blood flow using duplex ultrasound. Participants completed
two 5 min bouts of passive leg movement, each followed by 5 min of stationary rest. Leg blood flow
was recorded throughout the passive leg movement trials.
Participants consumed either 140 mL of concentrated beetroot juice (Beet It, James White Sports
Drinks, Ashbocking, Suffolk, UK) or 140 mL of a placebo drink (NO3−-depleted beetroot juice, also from
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James While Sports Drinks, Ashbocking, Suffolk, UK), independently verified to have <0.001 g NO3−
by our group and others [47]. The beetroot juice and the placebo looked, smelled and tasted the same
and they were packaged identically. The dose (140 mL) of NO3−-rich beet juice provided 800 mg of
NO3−, while the NO3−-depleted version supplied negligible NO3−.
Participants rested quietly, reading or completing crosswords or sudoku. Post-juice measures
began 2 h after juice was consumed to account for the delay between ingestion and physiological effect
due to entero-salivary circulation [31]. Post-juice measures were carried out with the same order and
timing as the pre-juice measures.
2.5. Measurements
Augmentation Index. The brachial pressure cuff of the SphygmoCor XCEL device (AtCor
Medical, West Ryde, NSW, Australia) was applied to the right arm, midway between the shoulder
and elbow. Brachial wave forms were recorded and a validated digital signal processing and transfer
function was applied to generate central aortic pressure wave forms [48]. From this, central systolic
and diastolic pressures were derived. Wave form separation enables the calculation of total central
pulse pressure (central systolic—central diastolic pressure) and augmentation pressure, which is the
difference between central systolic pressure and the pressure at the deflection point where forward and
backward wave forms converge. Augmentation index (AIx) was then determined as: [augmentation
pressure (∆P)/total central pulse pressure (cPP)]× 100, expressed as a percentage [49,50]. Augmentation
index is influenced by heart rate and, therefore, values were corrected for a standard heart rate of
75 beats·min−1 (AIx75) [51].
Pulse Wave Velocity. Carotid-femoral pulse wave transit time was measured by simultaneously
recording pulse waves at the right carotid artery and the right femoral artery with the SphygmoCor
XCEL device. A high fidelity applanation tonometer was positioned on the carotid artery, 2–3 cm below
the mandible, and a thigh cuff was applied to the right leg, 20 cm below the inguinal fold. For each
participant, the cuff position was standardised for all measurements. Once a consistent carotid pulse
signal was obtained that exceeded the quality control threshold within the software, the thigh cuff
was inflated to 80 mmHg to obtain the coinciding femoral pulse waves. Simultaneous carotid and
femoral pulse waves were recorded for 10 s and an average pulse wave transit time was calculated.
Conforming with consensus recommendations, the surface distance between the measurement sites
was measured and multiplied by 80% [52]. Pulse wave velocity was calculated as: distance (m)/pulse
wave transit time (s) [49].
Flow Mediated Dilatation. FMD of the superficial femoral artery (SFA) was measured according
to established best-practice guidelines [32]. A high-resolution Doppler ultrasound system (Terason
T3000, Burlington, MA, USA) and a 12 MHz multi-frequency linear array probe were used in
duplex mode to simultaneously capture vessel images (B-mode) and blood flow velocity (Doppler).
The insonation angle was set at ≤60◦ relative to the vessel, and image settings were optimised with
the depth and focus kept consistent for each participant. Image and flow velocity data were recorded
continuously throughout FMD procedures and all data were saved for off-line analysis (Camtasia
Studio, Techsmith, Okemos, MI, USA). All measures were performed by a single trained operator
(MW) using the participant’s right thigh and leg. Baseline SFA diameter and blood flow velocity were
recorded for 60 s. A contoured thigh cuff (Hokanson, Bellevue, WA, USA), positioned distal to the
site of insonation at mid-thigh level, was then rapidly inflated to 220 mmHg for 5 min to completely
occlude leg blood flow. Recording of vessel diameter and blood flow velocity then continued for 5 min
following the rapid release of cuff pressure.
A custom-designed software program, previously validated [53,54] for automated edge-detection
and wall tracking, was used for all vessel diameter and blood flow velocity measurements. Change
in diameter was calculated as: peak diameter - baseline diameter; and FMD (%) as: (change in
diameter/baseline diameter)× 100. Reactive hyperaemia was the peak flow rate and reactive hyperaemia
area-under-the-curve was total blood flow (mL·s−1) for 1 min after the release of cuff pressure. Shear
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rate (an estimate of shear stress) was quantified as: (mean blood velocity × 4)/vessel diameter. Shear
rate area-under-the-curve was calculated for the duration between the release of cuff pressure to the
time of peak vessel dilation.
Passive Leg Movement Hyperaemia. Passive leg movement hyperaemia was measured in
accordance with established guidelines [55]: at the common femoral artery at least 2 cm proximal to
the bifurcation of the superficial and deep femoral arteries. High-resolution ultrasound (Terason T3000,
Burlington, MA, USA) and a 12 MHz multi-frequency linear array probe were used for continuous
image and flow velocity capture during passive leg movement procedures. All data were recorded for
off-line analysis using recording software (Camtasia Studio, Techsmith, Okemos, MI, USA). Automated
edge-detection and blood flow analysis software was used to measure vessel diameter and blood flow
velocity [54]. Leg blood flow was calculated as: pi × (vessel diameter/2)2 × TAV × 60, where common
femoral artery diameter was measured in cm, and TAV (time averaged velocity) was Doppler blood
flow velocity measured in cm·s−1. Blood flow was measured each second (1 Hz). As we described
previously [13], for each participant, on each occasion, passive leg movement data were collected in
duplicate and averaged, or where one trial had obvious movement artefact, the trial without artefact
was used. Baseline leg blood flow was the average flow during the final minute of rest prior to
commencing passive leg movement. Area under the curve was the summed blood flow response for
60 s following the onset of passive movement. The blood flow data during passive movement were
smoothed using a 5 s rolling average. The passive leg movement hyperaemia data are expressed as
delta blood flow and delta area under the curve, where baseline leg blood flow has been subtracted
from the hyperaemic response.
Plasma NO3− and NO2−. During experimental visits, 4 mL blood samples were drawn from an
antecubital vein into a tube containing lithium heparin. Blood samples were immediately centrifuged
at 3400 g for 3 min and plasma was aliquoted in 0.5 mL samples into cryovials which were snap frozen
in liquid nitrogen and stored at −80 ◦C for later analysis.
Plasma samples were thawed at room temperature (21 ◦C) in the dark and all assays were
performed within 10 min of thawing. Measurement of plasma [NO3−] and [NO2−] was carried out by
gas-phase chemiluminescence using a nitric oxide analyser and following manufacturer’s instructions
(NOA 280i; Sievers Instruments, Boulder, CO, USA) [56]. To determine the [NO2−], potassium iodide
in acetic acid was used as the reductant, which converts NO2− to NO but does not reduce higher oxides
of nitrogen such as NO3−. Prior to the measurement of plasma [NO3−], samples were deproteinated
using zinc sulphate (ZnSO4)/sodium hydroxide (NaOH) precipitation. This was performed by adding
200 µL of plasma to 400 µL of ZnSO4 (10% w/v) and 400 µL of 0.5M NaOH. The solution was vortexed
for 30 s and left to stand at 22◦C for 15 min, centrifuged at 4000 g for 5 min and the supernatant
fraction was collected and used for determination of [NO3−]. The [NO3−] was determined using a
reductant of vanadium chloride in 1 M HCl at 90◦C. The [NO3−] and [NO2−] in samples was calculated
by converting the nitric oxide analyser signal into analyte concentration using a standard curve of
known concentrations of sodium NO3− or NO2−. The area under the curve was determined using
Origin software (version 7.1).
2.6. Statistics
As the effect of dietary NO3− on superficial femoral artery FMD and passive leg movement
hyperaemia has not been previously described, sample size was calculated from data presented by
Rammos et al [30]. Following a dose of dietary NO3−, brachial FMD increased from 6.0 ± 0.8% to
6.5 ± 0.8%, for older adult males (63 ± 5 years). Assuming a similar effect size (0.79) and variance,
with power at 0.99 and an alpha level of 0.05, we determined a priori that 10 participants in a cross-over
design would be needed to demonstrate a significant effect [57]. To allow for the possibility of a smaller
effect size in leg vessel dilation, and to improve the likelihood of finding significance in other measures
of interest, we selected a sample size of 15 participants.
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Investigators were blinded to test condition until all image and blood flow analyses were complete.
Statistical analyses were performed using SPSS (IBM SPSS Statistics, Ver24, Armonk, NY, USA).
Two-factor (time × condition) mixed ANOVA for repeated measures was used to compare the NO3− vs.
placebo days for all variables. Where ANOVA revealed a significant F test, pair-wise comparisons were
examined to identify the specific location of differences. Where delta data were used to compare NO3−
vs. placebo trials, one-way ANOVA was used. In addition, to conform with recent recommendations
for FMD analysis [58], statistical procedures included linear mixed model (LMM) analysis on the
logarithmically transformed change in vessel diameter. Baseline vessel diameter and shear rate may
affect the magnitude of the FMD (%) response [59], therefore they were included in the LMM analysis
as co-variates. This allometric scaling approach robustly accounts for the small variations in baseline
vessel diameter between trials. Flow mediated dilatation was also expressed as (FMD %)/(shear rate
AUC) to control for shear rate as a potential confounder [60]. Statistical significance was accepted at
p < 0.05. All data are expressed as mean ± standard deviation or 95% confidence intervals.
3. Results
3.1. Participant Characteristics
Participant characteristics are displayed in Table 1.
Table 1. Participant characteristics.
Participants (n) 15
Age (years) 69 ± 4
Weight (kg) 83 ± 10
Height (cm) 177 ± 8
BMI (kg·m2) 26.6 ± 3.5
ABI 1.25 ± 0.13
Systolic BP (mmHg) 131 ± 13
Diastolic BP (mmHg) 75 ± 8
Diuretics (%) 0
ARB/ACE inhibitors (%) 0
β-blockers (%) 0
Ca2+ channel blockers (%) 0
Statins (%) 27
Data are presented as mean ± SD or as sample frequency (%). BMI, body mass. index; ABI, ankle brachial index; BP,
blood pressure, where systolic and diastolic blood pressure were recorded in the brachial artery in a seated position;
ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme.
3.2. Plasma NO3− and NO2−
There was no change in plasma NO3− or plasma NO2− with placebo; however, following NO3−
supplementation, there was a 16.1-fold (95% CI: 13.7–18.5-fold, p < 0.001) increase in circulating plasma
NO3− and an 8.6-fold (95% CI: 6.6–10.6-fold, p < 0.001) increase in plasma NO2− compared to pre-NO3−
(Table 2).
Table 2. Blood plasma NO3− and NO2−.
Measure Pre-Placebo Post-Placebo Pre-NO3− Post-NO3−
Time × Condition
(p-Value)
Plasma NO3− (µM)
41
(31–51)
43
(35–52)
42
(34–50)
617 *
(572–663) <0.001
Plasma NO2− (nM)
108
(42–174)
87
(38–135)
101
(66–136)
832 *
(526–1139) <0.001
Data are mean (95% confidence interval). p-values refer to the significance of the F-statistic of the two-way (time ×
condition) repeated measures ANOVA. * Plasma NO3− and NO2− were significantly increased post-NO3− compared
to pre-NO3−, while there was no difference pre- to post-placebo.
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3.3. Blood Pressure, Pulse Wave Velocity, and Augmentation Index
Brachial blood pressure, central systolic pressure, central pulse pressure, and pulse wave velocity
were not different at baseline and did not change with either NO3− or placebo. However, there was a
significant interaction where augmentation index was lower following the NO3− supplement compared
with placebo (Table 3).
Table 3. Heart rate, blood pressure, augmentation index, and pulse wave velocity.
Measure Pre-Placebo Post-Placebo Pre-NO3− Post-NO3− Time × Condition (p-Value)
Heart rate (b·min−1) 62(56–68)
60
(54–67)
60
(54–65)
59
(54–63) 0.545
Systolic blood pressure (mmHg) 128(122–134
130
(124–135)
126
(120–131)
127
(121–133) 0.992
Diastolic blood pressure (mmHg) 74(69–78)
75
(70–79)
74
(70–77)
72
(67–76) 0.067
Central systolic pressure (mmHg) 116(111–122)
117
(113–122)
114
(110–119)
114
(109–119) 0.609
Central pulse pressure (mmHg) 41(37–46)
42
(37–47)
40
(34–45)
41
(36–46) 0.712
Augmentation index (AIx75) 19.4(16.0–22.8)
14.7
(11.0–18.4)
17.3
(13.7–20.9)
8.5 *
(4.2–12.8) 0.027
PWV (m·s−1) 11.7(10.4–13.0)
11.7
(10.8–12.5)
12.2
(10.3–14.2)
11.5
(10.4–12.7) 0.143
Data are expressed as mean (95% confidence interval). All measures were taken while supine, following 15 min
of rest. p-values refer to the significance of the F-statistic of the two-way (time × condition) repeated measures
ANOVA. AIx75, augmentation index corrected to a standard heart rate of 75 beats·min−1; PWV, pulse wave velocity.
*AIx75 was significantly lower post-NO3− than Pre-NO3− and the placebo conditions.
3.4. Flow Mediated Dilatation
Flow mediated dilatation and the associated variables are presented in Table 4 and Figure 1.
Superficial femoral artery diameter was similar prior to cuff occlusion on all occasions (pre/post,
NO3−/placebo), providing a consistent baseline measure for FMD tests. Reactive hyperaemia peak flow
rate and AUC were similar on all occasions, as was the response of shear rate. Flow mediated dilatation
was not different pre- to post-placebo; however, FMD was significantly increased post-NO3− compared
to pre-NO3− (Table 4), a difference which persisted when FMD was log transformed (allometric scaled
FMD), expressed relative to shear rate (FMD·SRAUC−1), and when it was expressed as percent change
(Figure 1). One participant failed to dilate (FMD was <2% on all tests). This is an occurrence that
has been acknowledged in other FMD studies [61] and this participant’s FMD data were excluded,
however this did not change the significance of F-scores in the statistical analysis.
Table 4. Flow mediated dilatation parameters.
Measure Pre-Placebo Post-Placebo Pre-NO3− Post-NO3− Time × Condition (p-Value)
Baseline SFA diameter (mm) 6.93(6.61–7.24)
7.02
(6.57–7.46)
6.95
(6.66–7.24)
7.09
(6.82–7.36) 0.783
RH peak flow (mL·min−1) 1093(968–1218)
1140
(1005–1275)
1160
(1040–1279)
1142
(972–1314) 0.361
RH AUC (mL) 367(306–428)
417
(363–470)
395
(352–437)
409
(342–477) 0.396
Time to peak dilation (s) 144(121–168)
130
(109–150)
124
(108–150)
140
(126–155) 0.086
Response shear (AUC) 9997(8014–11980)
10904
(8870–12938)
9038
(7787–10288)
9199
(7545–10854) 0.406
Absolute FMD (mm) 0.30(0.26–0.35)
0.29
(0.24–0.32)
0.28
(0.24–0.32)
0.37 *
(0.31–0.42) 0.002
FMD·SRAUC−1 (103·s−1) 5.31(3.47–7.16)
4.24
(2.60–5.90)
4.99
(3.22–6.76)
6.40 *
(4.39–8.41) <0.001
Allometric scaled FMD (%) 4.07(3.38–4.76)
3.91
(3.22–4.61)
3.76
(3.07–4.46)
4.75 *
(4.06–5.45) 0.010
#
All data are mean (95% confidence interval). p-values refer to the significance of the F-statistic in two-way (time ×
condition) repeated measures ANOVA, except allometric scaled FMD, where the p-value (#) refers to the significance
in the linear mixed model (LMM) analysis. Allometric scaled FMD was logarithmically transformed to account for
variance in base diameter during linear mixed model analysis and the values in the table have been back-logged for
clarity. SFA, superficial femoral artery; RH, reactive hyperaemia; AUC, area under the curve; FMD, flow mediated
dilatation; SR, shear rate. * Post- NO3− is significantly different from pre-NO3− and the placebo conditions.
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4. Discussion
The primary aim of this placebo-controlled, double-blind, cross-over design study was to determine
whether NO3− supplementation would improve vascular function in older adults. The main findings
are that an acute dose of dietary NO3− increased plasma NO2−, suggesting increased NO bioavailability,
and this was associated with enhanced lower limb FMD and improved (lower) pressure augmentation
index. However, dietary NO3− did not alter pulse wave velocity or the hyperaemic response to passive
leg movement.
Our interest in the impact of NO3− supplementation on vascular function in the leg began with
the observation that NO3− supplementation was associated with a decrease in blood pressure [62]
and an improvement in exercise tolerance in older adults [22], and in patients with peripheral arterial
disease [23,24], heart failure with preserved ejection fraction [47], and stable angina [63]. It was
proposed that dietary NO3− may enhance plasma NO2−, which may increase NO bioavailability [31].
Nitric oxide may then reduce blood pressure by improving vessel dilation and reducing arterial
stiffness [62] and may also contribute to enhanced exercise tolerance [22] by increasing blood flow.
All participants responded to NO3− supplementation with an increase in blood plasma NO3− and
NO2− while there was no change in plasma NO3− or NO2− during the placebo trial. The link between
NO3− ingestion, circulating plasma NO2−, and NO bioavailability has been clearly defined [31],
but individual responses can vary widely due to factors such as source and dose of NO3−, dietary
restriction prior to or during the experiment, oral microbiome and oral hygiene, medication and
supplement use, and fitness status [17,64,65]. We considered these factors in our study design and
our participants showed an average 8.6-fold increase in circulating plasma NO2− following NO3−
supplementation. This increase is similar in magnitude to other well-controlled studies investigating
NO3− supplementation in older adults [23,66] and indicates NO bioavailability was likely enhanced.
Our results demonstrate that FMD in the superficial femoral artery increased following NO3−
supplementation. Four previous studies with varied NO3− doses (180–397 mg·day−1 and 9.3 mg·kg
body weight−1), sources (beetroot juice, spinach, and NaNO3), and treatment schedules (acute vs.
ongoing) have indicated that NO3− supplementation can increase brachial artery FMD in older
adults [28–30,35]. A point of difference for the present study is that FMD was measured in the
superficial femoral artery of participants, as opposed to the arm, as this site is likely to be of greater
relevance to walking capacity and exercise tolerance. Additionally, the effect of age is not uniform
across the cardiovascular system [11,12,37], and upper limb FMD is not predictive of FMD in the
lower limbs [37]. Differences in the FMD response between upper and lower limbs may be related
to differences in vessel size [59], the thickness of the vessel walls [67], or it may reflect the increased
vulnerability of the lower limbs to the detrimental effects of aging and cardiovascular disease [11,12,36].
For the first time, our study establishes that dietary NO3− improves FMD in the superficial femoral
artery, reflecting an enhanced endothelial function in the legs of older adults.
Previous studies of the effect of NO3− supplementation on brachial FMD in older adults report
inconsistent findings, with some indicating an increase as noted above [28–30,35], while others report no
effect [23,68]. Similar to our study, the previous studies demonstrating a positive effect of NO3− on FMD
included participants who did not take medication and were free from disease [28,30,35,69]. The two
studies reporting no change in brachial FMD following NO3− supplementation included participants
who were taking anti-hypertensive and anti-platelet medications. Anti-hypertensive medications are
likely to have a vasodilating effect [70] which may mask any effect of NO3− supplementation. Another
possible explanation for the null findings is that these two studies included participants who had
been diagnosed with peripheral arterial disease [23] and type II diabetes [68]. Low brachial FMD is
a sub-clinical marker for cardiovascular disease risk [32,34], which does not appear to change with
improvements in walking distance for PAD patients [23], however there is evidence to suggest that
FMD in the leg, rather than the arm, may be a more sensitive measure in this patient group [24,71].
Regardless, the current mix of findings is promising, but indicates a need for further investigation into
the therapeutic benefits of dietary NO3− supplementation for individuals with cardiovascular disease.
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Reactive hyperaemia did not increase following NO3− supplementation, suggesting there was
no change in vasodilation of arterioles downstream from the site of cuff occlusion. Importantly,
this indicates that the increase in FMD was not a result of increased shear stress. One explanation
for this finding is the dampening effect that dietary NO3− may have on the abundance of reactive
oxygen species [72,73]. Elevated production of reactive oxygen species is detrimental to vascular
function, primarily because it leads to a loss in bioactive NO [74,75]. It is possible that NO3−
supplementation enhanced the antioxidant defence system [76,77], reducing the rate of reactive
oxygen species production. A decrease in reactive oxygen species may have facilitated an increase
in FMD, the magnitude of which might reflect eNOS-derived NO [32], rather than NO produced via
the NO3−–NO2−–NO pathway. This theory is supported by evidence of improved FMD following
antioxidant treatments, such as vitamin E [78,79] and vitamin B3 (niacin) [80]. Dietary NO3− from
vegetables such as beetroot may reduce oxidative stress more than individual vitamins or minerals
because it may simultaneously restore redox imbalance and enhance NO generation [72]. This proposal
warrants further exploration.
Passive leg movement hyperaemia, a recently established measure of NO-dependent vascular
function [41,42], did not change following NO3− supplementation. Passive leg movement hyperaemia
is measured at the common femoral artery, which typically does not dilate during this assessment, and
the hyperaemic response is understood to reflect downstream arteriole endothelium-dependent flow
regulation [55]. Passive leg movement studies have used pharmacological NOS blockade to demonstrate
an essential role of NO in the hyperaemic response [43,81], but it is interesting that NOS blockade
only suppressed hyperaemia in young participants. The null response in older participants with both
NOS blockade and NO3− supplementation suggests that passive leg movement hyperaemia may not
be a sensitive test for fluctuations in NO bioavailability in older adults. Collectively, our findings of
increased FMD, unchanged reactive hyperaemia, and unchanged passive leg movement hyperaemia,
indicate that, in the leg, conduit artery function is sensitive to a dose of dietary NO3−, while downstream
arteriole flow regulation is not. While the increase in FMD following NO3− supplementation indicates
an improvement in lower limb endothelial function, the lack of change in reactive hyperaemia and
passive leg movement hyperaemia raises questions about the functional relevance of this finding.
The impact of dietary NO3− on femoral blood flow during exercise has not been described in older
adults. Given that conditions of low oxygen tension and low pH that may be observed during exercise
promote reduction of NO2− to NO, future studies should investigate whether exercise blood flow
responses are augmented with dietary NO3−.
Another explanation for the absence of an effect of NO3− supplementation on passive leg
movement hyperaemia is insufficient stimulation. Studies exploring NO3− supplementation in hypoxia
demonstrate that the conversion of NO2− to NO is facilitated by perturbations to homeostasis, such as a
reduction in oxygen tension [21,82,83]. In the present study, during passive leg movement, participants
were instructed to maintain relaxed muscles. Passive leg movement causes the muscle tissues to
stretch without registering EMG activity or increasing muscle oxygen uptake [40,41,84,85], thereby not
imposing any metabolic stress. The value of passive leg movement as an experimental model is that it
avoids activation of other vasodilating systems associated with exercise, such as prostacyclin [84,86],
revealing a blood flow response that reflects NO bioavailability. However, in our study, it is possible
that elevated plasma NO2− did not increase the hyperaemic response to passive leg movement because
metabolic stress is necessary to activate mechanisms that produce NO from NO2−.
Resting leg blood flow, assessed immediately prior to the onset of passive leg movement, was
similar post-NO3− and pre- and post-placebo, however resting flow was lower pre-NO3−. Trial order
was randomised for each participant and this measure was taken prior to ingestion of NO3−. There
was no reason that we can identify to explain why leg blood flow was lower pre-NO3−.
Augmentation index tended to be lower in the afternoon during both the NO3− and placebo
trials, although the difference only reached significance following administration of dietary NO3−.
The time-related effect may reflect a redistribution of blood volume and reduced cardiac preload [87] or
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there may be a diurnal effect in augmentation index. We suggest time of day should be standardised for
this measure. Stiffening of arterial vessels is a risk factor for cardiovascular disease [88,89], as age-related
stiffening in the peripheral vessels can cause reflected waveforms to meet outgoing pulse waves closer
to the heart with higher pressure, impeding blood flow and putting strain on the left ventricle [90]. For
this reason, it is advantageous to reduce downstream resistance in older adults [91,92] and a reduction
in the augmentation index after a dose of dietary NO3− suggests a temporary cardiovascular benefit.
Endothelial function and arterial stiffness are related [90] and measures of FMD and augmentation index
have previously been shown to be associated [93]. The fact that both improved in the present study
suggests that both may be sensitive to enhanced NO bioavailability, however FMD and augmentation
index were not correlated. Lower augmentation index indicates an improvement in peripheral
vessel compliance and this finding agrees with other studies that have measured augmentation index
following NO3− supplementation in older adults [28–30].
Pulse wave velocity was unchanged by a dose of dietary NO3−. This concurs with some [94–96]
but not all reports [28–30]. Systolic and diastolic blood pressures were also unchanged following
NO3− supplementation. There are equivocal reports in the literature regarding whether dietary NO3−
reduces blood pressure in older adults [27,97]. There are many factors that influence blood pressure,
including structural properties of vessels, neural input, and local vasodilator and constrictor regulation
throughout the vascular network [98]. However, the finding of no change in pulse wave velocity is
consistent with the absence of any change in blood pressure in this study.
Limitations
Participant use of medication for cardiovascular conditions may mask the effect of NO3−
supplementation. Some participants in our study were taking low dose statins and, in addition
to lowering cholesterol, statins may improve endothelial NOS expression and improve baseline NO
bioavailability [99]. The fact that baseline plasma NO2− was low, even among those who were taking
statins, suggests low NO status irrespective of medication use. During the study, there were no changes
to the use of statins, or schedule or timing of dose for any individual, and experiment trials were
carried out on the same day and time, separated by one week. Further, the cross-over design enabled
participants to act as their own controls.
Sex differences have been noted in the literature regarding the effectiveness of dietary NO3−
supplementation [100–103]. There is evidence of greater circulating NO2− in females, which is
associated with lower blood pressure [100]. This is consistent with demographic studies indicating
that blood pressure is lower for post-menopausal women than age-matched men [104] and it is also
supported by evidence of increased NO production in women [105]. It has been proposed that elevated
NO2− in females leads to a saturation effect that may reduce sensitivity to NO3− supplementation
compared to men [106]. This investigation involved male participants and may not be generalisable to
females. Future study is needed to confirm these findings in female participants.
5. Conclusions
In this study of older adult males, dietary NO3− increased plasma NO2− and FMD in the
conduit vessels of the leg. Future research should investigate whether there is an association
between improvements in leg FMD and improvements in exercise tolerance for older adults following
NO3− supplementation.
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